Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NK Cells for COVID-19
NCT04634370Phase 1Unknown
- Sponsor
- Hospital de Clínicas de Porto Alegre
- Start
- Jan 2021
- Primary completion
- Mar 2021
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Natural Killer Cells in coronavirus disease 2019 (COVID-19), sponsored by Hospital de Clínicas de Porto Alegre. Primary endpoints: Overall survival at 30 days, Changes on inflammatory C-reactive protein at 60 days and 4 more. Status: unknown.
02
Drugs
Natural Killer Cells
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04634370.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04634370.